Ruffer LLP Increases Holdings in Gilead Sciences, Inc. $GILD

Ruffer LLP raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 304.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 182,343 shares of the biopharmaceutical company’s stock after purchasing an additional 137,246 shares during the quarter. Gilead Sciences comprises about 1.1% of Ruffer LLP’s investment portfolio, making the stock its 28th biggest position. Ruffer LLP’s holdings in Gilead Sciences were worth $20,240,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Paulson Wealth Management Inc. grew its stake in shares of Gilead Sciences by 17.9% in the third quarter. Paulson Wealth Management Inc. now owns 3,820 shares of the biopharmaceutical company’s stock valued at $424,000 after buying an additional 581 shares in the last quarter. AE Wealth Management LLC lifted its position in shares of Gilead Sciences by 24.2% during the third quarter. AE Wealth Management LLC now owns 43,873 shares of the biopharmaceutical company’s stock worth $4,870,000 after purchasing an additional 8,554 shares in the last quarter. LRI Investments LLC grew its holdings in Gilead Sciences by 9.7% during the 3rd quarter. LRI Investments LLC now owns 1,622 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 144 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Gilead Sciences by 9.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 610,834 shares of the biopharmaceutical company’s stock worth $67,803,000 after buying an additional 54,068 shares during the period. Finally, Ballentine Partners LLC lifted its holdings in Gilead Sciences by 4.8% in the 3rd quarter. Ballentine Partners LLC now owns 22,672 shares of the biopharmaceutical company’s stock worth $2,517,000 after buying an additional 1,041 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Kelly A. Kramer sold 2,805 shares of the business’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $127.10, for a total transaction of $356,515.50. Following the completion of the transaction, the director directly owned 1,339 shares of the company’s stock, valued at $170,186.90. The trade was a 67.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the completion of the sale, the chief executive officer owned 566,698 shares in the company, valued at $76,504,230. The trade was a 16.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 247,397 shares of company stock valued at $31,986,612 over the last three months. 0.27% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of analyst reports. Rothschild & Co Redburn lifted their target price on Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. BMO Capital Markets raised their price objective on Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a research note on Monday. UBS Group upped their target price on Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research report on Monday. HSBC increased their target price on Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a research note on Wednesday, December 10th. Finally, The Goldman Sachs Group lifted their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a research note on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $135.36.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $139.72 on Thursday. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $141.71. The business has a 50 day simple moving average of $124.76 and a 200-day simple moving average of $119.24. The company has a market capitalization of $173.35 billion, a price-to-earnings ratio of 21.66, a price-to-earnings-growth ratio of 0.74 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. Gilead Sciences’s revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the company posted $2.02 earnings per share. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.